检索结果-南通市图书馆

Efficacy and safety of utidelone for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer who have failed standard second-line treatment:A phase 2 clinical trial(BG01-1801)

引用

Cancer Pathogenesis and Therapy 2024年第2期2卷 103-111页

作者： Yuankai Shi gongyan chen Yanqiu Zhao Jing Zhao Lin Lin Department of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences&Peking Union Medical CollegeBeijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted DrugsBeijing 100021China Department of Respiration Harbin Medical University Cancer HospitalHarbinHeilongjiang 150040China Respiratory Department of Internal Medicine Henan Provincial Cancer HospitalZhengzhouHenan 450003China Department of Pulmonary and Critcal Care Medicine Peking Union Medical College HospitaChinese Academy of Medical Sciences&Peking Union Medical College Beijing100021China

Background:Chemotherapy remains the standard-of-care for many patients with locally advanced or metastatic non-small-cell lung cancer(NSCLC),but acquired resistance presents challenges.The aim of this open-label,multicenter phase 2 clinical trial was to determine the efficacy and safety of utidelone,a novel genetically engineered epothilone analog and microtubule-stabilizing agent,as a third-or later-line treatment for locally advanced ormetastatic NSCLC.Methods:Patients who had failed standard second-line treatment(including platinum-containing chemotherapy or targeted therapy)received utidelone(40 mg/m?via intravenous injection daily,day 1-5)every 21 days.The primary endpoint was the objective response rate(ORR).Secondary endpoints were the duration of response(DoR),progression-free survival(PFS),overall survival(OS),and safety.Results:From March 12,2019 to January 18,2021,26 pretreated patients with locally advanced or metastatic NSCLC(100%of patients had received prior platinum and 65.4%patients had received prior taxane treatment)were enrolled(80.8%of patients had adenocarcinoma).At baseline,nine(34.6%)patients had received secondline treatment,10(38.5%)patients had received third-line treatment,and seven(26.9%)patients had received fourth-or later-line treatment.By the data cut-off date of August 10,2021,the median follow-up was 7.49 months(range,1.4-26.7 months).The ORR was 15.4%(95%confidence interval[CI],4.4%-34.9%)in the intention-totreat(ITT)cohort(N=26)and 19.0%(95%CI,5.4%-41.9%)in the per-protocol(PP)cohort(N=21).The disease control rate was 69.2%(95%CI,48.2%-85.7%)and 81.0%(95%CI,58.1%-94.6%)in the ITT and PP cohorts,respectively.The median DoR was 4.1 months(95%CI,3.1-5.1 months)in the ITT cohort.The median PFS was 4.37 months(95%CI,2.50-5.29 months)in the ITT cohort and 4.37 months(95%CI,2.50-9.76 months)in the PP cohort.The median OS was not reached,and the 12-month OS rate was 69%(95%CI,45.1%-84.1%).Grade 3/4 treatment-emergent adverse events occurred in 38.5%of patients,and the most common was

关键词： Utidelone Locally advanced or metastatic non-small-cell lung cancer Efficacy Platinum-and taxane-refractory

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

IMpower210:A phase Ⅲ study of second-line atezolizumab vs. docetaxel in East Asian patients with non-small cell lung cancer

引用

Chinese Journal of Cancer Research 2024年第2期36卷 103-113页

作者： Yi-Long Wu Shun Lu gongyan chen Jianxing He Jifeng Feng Yiping Zhang Liyan Jiang Hongming Pan Jianhua Chang Jian Fang Amy Cai Lilian Bu Jane Shi Jinjing Xia Guangdong Lung Cancer Institute Guangdong Provincial Key Laboratory of Translational Medicine in Lung CancerGuangdong Provincial People's Hospital&Guangdong Academy of Medical SciencesSouthern Medical UniversityGuangzhou 510080China Shanghai Lung Cancer Center Shanghai Chest HospitalSchool of MedicineShanghai Jiao Tong UniversityShanghai 200025China Department of Respiration Harbin Cancer HospitalHarbin Medical UniversityHarbin 150081China Department of Thoracic Oncology and Surgery the First Affliated Hospital of Guangzhou Medical UniversityGuangzhou 510120China Department of Medical Oncology Jiangsu Cancer HospitalNanjing 210009China Department of Medical Oncology Zhejiang Cancer HospitalHangzhou 330022China Department of Pulmonary Medicine Shanghai Chest HospitalShanghai Jiao Tong UniversityShanghai 200030China Department of Medical Oncology Sir Run Run Shaw HospitalZhejiang University School of MedicineHangzhou 310016China Department of Medical Oncology Shenzhen HospitalCancer Hospital of Chinese Academy of Medical SciencesShenzhen 518116China Department of Thoracic Oncology Beijing Cancer HospitalBeijing 100142China Product Development Shanghai Roche Pharmaceutical LtdShanghai 201203China

Objective: IMpower210(NCT02813785) explored the efficacy and safety of single-agent atezolizumab vs.docetaxel as second-line treatment for advanced non-small cell lung cancer(NSCLC) in East Asian patients.Methods: Key eligibility criteria for this phase Ⅲ, open-label, randomized study included age ≥18 years;histologically documented advanced NSCLC per the Union for International Cancer Control/American Joint Committee on Cancer staging system(7th edition);Eastern Cooperative Oncology Group performance status of 0 or 1;and disease progression following platinum-based chemotherapy for advanced or metastatic NSCLC. Patients were randomized 2:1 to receive either atezolizumab(1,200 mg) or docetaxel(75 mg/m^(2)). The primary study endpoint was overall survival(OS) in the intention-to-treat(ITT) population with wild-type epidermal growth factor receptor expression(ITT EGFR-WT) and in the overall ITT population.Results: Median OS in the ITT EGFR-WT population(n=467) was 12.3 [95% confidence interval(95% CI),10.3-13.8] months in the atezolizumab arm(n=312) and 9.9(95% CI, 7.8-13.9) months in the docetaxel arm[n=155;stratified hazard ratio(HR), 0.82;95% CI, 0.66-1.03]. Median OS in the overall ITT population was 12.5(95% CI, 10.8-13.8) months with atezolizumab treatment and 11.1(95% CI, 8.4-14.2) months(n=377) with docetaxel treatment(n=188;stratified HR, 0.87;95% CI, 0.71-1.08). Grade 3/4 treatment-related adverse events(TRAEs) occurred in 18.4% of patients in the atezolizumab arm and 50.0% of patients in the docetaxel arm.Conclusions: IMpower210 did not meet its primary efficacy endpoint of OS in the ITT EGFR-WT or overall ITT populations. Atezolizumab was comparatively more tolerable than docetaxel, with a lower incidence of grade3/4 TRAEs.

关键词： Atezolizumab East Asia non-small cell lung cancer programmed death-ligand 1 inhibitors monoclonal antibody

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Anlotinib as third- or further-line therapy for short-term relapsed small-cell lung cancer: subgroup analysis of a randomized phase 2 study (ALTER1202)

引用

Frontiers of Medicine 2022年第5期16卷 766-772页

作者： Jianhua Shi Ying cheng Qiming Wang Kai Li Lin Wu Baohui Han gongyan chen Jianxing He Jie Wang Haifeng Qin Xiaoling Li Department of Medical Oncology Linyi Cancer HospitalLinyi 276002China Department of Thoracic Medical Oncology Jilin Cancer HospitalChangchun 130012China Department of Internal Medicine Affiliated Cancer Hospital of Zhengzhou UniversityHenan Cancer HospitalZhengzhou 450003China Department of Pulmonary Oncology Tianjin Medical University Cancer Institute and HospitalTianjin 300060China Department of Thoracic Medical Oncology The Affiliated Cancer Hospital of Xiangya School of MedicineCentral South University(Hunan Cancer Hospital)Changsha 410031China Department of Respiratory Medicine Shanghai Chest HospitalShanghai Jiao Tong UniversityShanghai 200030China Department of Respiratory Medicine Harbin Medical University Cancer HospitalHarbin 150081China Department of Thoracic Surgery The First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou 510120China National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100021China Department of Pulmonary Oncology The Fifth Medical Centre of Chinese PLA General HospitalBeijing 100039China Department of Medical Oncology Liaoning Cancer HospitalShenyang 110042China

Patients with small-cell lung cancer (SCLC) relapse within months after completing previous therapies. This study aimed to investigate the efficacy and safety of anlotinib as third- or further-line therapy in patients with short-term relapsed SCLC from ALTER1202. Patients with short-term relapsed SCLC (disease progression within 3 months after completing ≥ two lines of chemotherapy) in the anlotinib (n = 67) and placebo (n = 34) groups were analyzed. The primary endpoint was progression-free survival (PFS). The secondary endpoints included overall survival, objective response rate (ORR), disease control rate, and safety. Anlotinib significantly improved median PFS/OS (4.0 vs. 0.7 months, P < 0.0001)/(7.3 vs. 4.4 months, P = 0.006) compared with placebo. The ORR was 4.5%/2.9% in the anlotinib/placebo group (P = 1.000). The DCR in the anlotinib group was higher than that in the placebo group (73.1% vs. 11.8%, P < 0.001). The most common adverse events (AEs) were hypertension (38.8%), loss of appetite (28.4%), and fatigue (22.4%) in the anlotinib group and gamma-glutamyl transpeptidase elevation (20.6%) in the placebo group. No grade 5 AEs occurred. For patients with short-term relapsed SCLC, third- or further-line anlotinib treatment was associated with improved survival benefit. Further studies are warranted in this regard.

关键词： anlotinib chemotherapy short-term relapsed small-cell lung cancer

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Third-line or above anlotinib in relapsed and refractory small cell lung cancer patients with brain metastases:A post hoc analysis of ALTER1202,a randomized,double-blind phase 2 study

引用

Cancer Innovation 2023年第3期2卷 181-190页

作者： Ying cheng Qiming Wang Kai Li Jianhua Shi Baohui Han Lin Wu gongyan chen Jianxing He Jie Wang Haifeng Qin Xiaoling Li Department of Thoracic Medical Oncology Jilin Cancer HospitalChangchunChina Department of Internal Medicine Affiliated Cancer Hospital of Zhengzhou UniversityHenan Cancer HospitalZhengzhouChina Department of Pulmonary Oncology Tianjin Medical University Cancer HospitalTianjinChina Department of Medical Oncology Linyi Cancer HospitalLinyiChina Department of Respiratory Medicine Shanghai Chest HospitalShanghai Jiaotong UniversityShanghaiChina Department of Thoracic Medical Oncology Hunan Cancer HospitalChangshaChina Department of Respiratory Medicine Harbin Medical University Cancer HospitalHarbinChina Department of Thoracic Surgery The First Affiliated Hospital of Guangzhou Medical UniversityGuangzhouChina Department of Thoracic Medical Oncology Cancer Hospital Chinese Academy of Medical SciencesBeijingChina Department of Pulmonary Oncology The Fifth Medical Centre of Chinese PLA General HospitalBeijingChina Department of Medical Oncology Liaoning Cancer Hospital and InstituteShenyangChina

Background:The prognosis of patients with small cell lung cancer(SCLC)and brain metastases(BM)was poor.This study aimed to explore the efficacy and safety of anlotinib as third-line or above treatment in SCLC with BM.Methods:This was a subgroup analysis of the ALTER1202 trial,which was a randomized,placebo-controlled trial aimed to evaluate the role of anlotinib as third-line treatment or above in patients with SCLC.This study included patients with BM at baseline.The efficacy and safety outcomes included progression-free survival(PFS),overall survival(OS),central nervous system(CNS),objective response rate(ORR),CNS disease control rate(DCR),time to CNS progression,and adverse events(AEs).Results:Twenty-one and nine patients with BM were included in the anlotinib and placebo groups,respectively.The median PFS and OS were 3.8 months(95%confidence interval[CI]:1.8-6.1)and 6.1 months(95%CI:4.1-8.0)in the anlotinib group.Anlotinib was associated with a significant improvement in PFS(hazard ratio[HR]=0.15,95%CI:0.04-0.51,p=0.0005)and OS(HR=0.26,95%CI:0.09-0.73,p=0.0061)than placebo.Anlotinib significantly prolonged the time to CNS progression(p<0.0001).The anlotinib group had a higher CNS DCR than placebo(95.2%vs.22.2%,p=0.0001).The most common grade 3 or higher AEs were increased lipase(19.0%),hypertension(14.3%),and hyponatremia(14.3%)in the anlotinib group.Conclusions:Anlotinib proved to have potential CNS activity and a manageable toxicity profile in patients with SCLC and BM,significantly delaying CNS progression.

关键词： anlotinib angiogenesis inhibitors brain metastasis advanced small cell lung cancer safety

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Multiplexed imaging of tumor immune microenvironmental markers in locally advanced or metastatic non-small-cell lung cancer characterizes the features of response to PD-1 blockade plus chemotherapy

引用

Cancer Communications 2022年第12期42卷 1331-1346页

作者： Fengying Wu Tao Jiang gongyan chen Yunchao Huang Jianying Zhou Lizhu Lin Jifeng Feng Zhehai Wang Yongqian Shu Jianhua Shi Yi Hu Qiming Wang Ying cheng Jianhua chen Xiaoyan Lin Yongsheng Wang Jianan Huang Jiuwei Cui Lejie Cao Yunpeng Liu Yiping Zhang Yueyin Pan Jun Zhao LiPing Wang Jianhua Chang Qun chen Xiubao Ren Wei Zhang Yun Fan Zhiyong He Jian Fang Kangsheng Gu Xiaorong Dong Tao Zhang Wei Shi Jianjun Zou Xuejuan Bai Shengxiang Ren Caicun Zhou Department of Thoracic Medical Oncology Shanghai Pulmonary HospitalTongji University School of MedicineShanghai 200433P.R.China Department of Respiratory Medicine Harbin Medical University Cancer HospitalHarbinHeilongjiang 150000P.R.China Department of Thoracic Surgery Oncology Yunnan Cancer Hospital&The Third Affiliated Hospital of Kunming Medical University&Yunnan Cancer CenterKunmingYunnan 650118P.R.China Department of Respiratory Medicine The First Affiliated Hospital of Zhejiang UniversityHangzhouZhejiang 310009P.R.China Department of Oncology Center The First Affiliated Hospital of Guangzhou University of Chinese MedicineGuangzhouGuangdong 510405P.R.China Department of Thoracic Medical Oncology Jiangsu Cancer Hospital&Jiangsu Institute of Cancer Research&The Affiliated Cancer Hospital of Nanjing Medical UniversityNanjingJiangsu 210009P.R.China Department of Respiratory Shandong Cancer Hospital&InstituteJinanShandong 250117P.R.China Department of Oncology Jiangsu Province HospitalNanjingJiangsu 210000P.R.China Department of Medical Oncology Linyi Cancer HospitalLinyiShandong 276000P.R.China Department of Oncology Chinese PLA General HospitalBeijing 100853P.R.China Department of Respiratory Medicine Henan Cancer HospitalZhengzhouHenan 450000P.R.China Department of Thoracic Oncology Jilin Cancer HospitalChangchunJilin 130012P.R.China Department of Medical Oncology-Chest Hunan Cancer HospitalChangshaHunan 410006P.R.China Department of Oncology Fujian Medical University Union HospitalFuzhouFujian 350001P.R.China Department of Thoracic Medical Oncology West China HospitalSichuan UniversityChengduSichuan 610000P.R.China Department of Respiration First Affiliated Hospital of Suzhou UniversitySuzhouJiangsu 215002P.R.China Department of Medical Oncology The First Bethune Hospital of Jilin UniversityChangchunJilin 130021P.R.China Pulmonary and Critical Care Medicine The First Affiliated Hospital University of Science Technology of ChinaHefeiAnhui 230036P.R.China De

Background:Although programmed cell death 1(PD-1)blockade plus chemotherapy can significantly prolong the progression-free survival(PFS)and overall survival(OS)in first-line settings in patients with driver-negative advanced non-small-cell lung cancer(NSCLC),the predictive biomarkers remain undetermined.Here,we investigated the predictive value of tumor immune microenvironmental marker expression to characterize the response features to PD-1 blockade plus chemotherapy.Methods:Tumor tissue samples at baseline were prospectively collected from 144 locally advanced or metastatic NSCLC patients without driver gene alterations who received camrelizumab plus chemotherapy or chemotherapy alone.Tumor immune microenvironmental markers,including PD-1 ligand(PDL1),CD8,CD68,CD4 and forkhead box P3,were assessed using multiplex immunofluorescence(mIF)assays.Kaplan-Meier curveswere used to determine treatment outcome differences according to their expression status.Mutational profiles were compared between tumors with distinct expression levels of these markers and their combinations.Results:Responders had significantly higher CD8/PD-L1(P=0.015)or CD68/PD-L1 co-expression levels(P=0.021)than non-responders in the camrelizumab plus chemotherapy group,while no difference was observed in the chemotherapy group.Patients with high CD8/PD-L1 or CD68/PD-L1 co-expression level was associated with significantly longer PFS(P=0.002,P=0.024;respectively)and OS(P=0.006,P=0.026;respectively)than those with low co-expression in camrelizumab plus chemotherapy group.When comparing survival in the camrelizumab plus chemotherapy with chemotherapy by CD8/PD-L1 co-expression stratification,significantly better PFS(P=0.003)and OS(P=0.032)were observed in high co-expression subgroups.The predictive value of CD8/PD-L1 and CD68/PD-L1 co-expression remained statistically significant for PFS and OS when adjusting clinicopathological features.Although the prevalence of TP53 or KRAS mutations was similar between patients with and without CD8/PD-L1 or CD68

关键词： Non-small-cell lung cancer PD-1 CD8 CD68 tumor immune microenvironment

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Paclitaxel liposome for injection (Lipusu) plus cisplatin versus gemcitabine plus cisplatin in the first-line treatment of locally advanced or metastatic lung squamous cell carcinoma: A multicenter, randomized, open-label, parallel controlled clinical study

引用

Cancer Communications 2022年第1期42卷 3-16页

作者： Jie Zhang Yueyin Pan Qin Shi Guojun Zhang Liyan Jiang Xiaorong Dong Kangsheng Gu Huijuan Wang Xiaochun Zhang Nong Yang Yuping Li Jianping Xiong Tienan Yi Min Peng Yong Song Yun Fan Jiuwei Cui gongyan chen Wei Tan Aimin Zang Qisen Guo Guangqiang Zhao Ziping Wang Jianxing He Wenxiu Yao Xiaohong Wu Kai chen Xiaohua Hu Chunhong Hu Lu Yue Da Jiang Guangfa Wang Junfeng Liu Guohua Yu Junling Li Jianling Bai Wenmin Xie Weihong Zhao Lihong Wu Caicun Zhou Department of Medical Oncology Shanghai Pulmonary Hospital&Thoracic Cancer InstituteTongji University School of MedicineShanghai 200433P.R.China Department of Chemotherapy Anhui Provincial HospitalHefeiAnhui 230001P.R.China Department of Oncology Fuzhou Pulmonary Hospital of FujianFuzhouFujian 350008P.R.China Department of Respiratory Medicine the First Affiliated Hospital of Zhengzhou UniversityZhengzhouHenan 450052P.R.China Department of Respiration Shanghai Chest HospitalShanghai Jiao Tong UniversityShanghai 200030P.R.China Cancer Center Union Hospital of Tongji Medical CollegeHuazhong University of Science and TechnologyWuhanHubei 430022P.R.China Department of Medical Oncology the First Affiliated Hospital of Anhui Medical UniversityHefeiAnhui 230032P.R.China Department of Respiration Henan Cancer HospitalZhengzhouHenan 450008P.R.China Department of Medical Oncology the Affiliated Hospital of Qingdao UniversityQingdaoShandong 266000P.R.China Department of Medical Oncology Hunan Cancer HospitalChangshaHunan 410013P.R.China Department of Pulmonary and Critical Care Medicine the First Affiliated Hospital of Wenzhou Medical CollegeShangcai villageWenzhouZhejiang 325000P.R.China Department of Medical Oncology the First Affiliated Hospital of Nanchang UniversityNanchangJiangxi 330006P.R.China Department of Medical Oncology Xiang Yang Central HospitalXiangyangHubei 441021P.R.China Department of Medical Oncology Renmin Hospital of Wuhan UniversityWuhanHubei 430060P.R.China Department of Respiration General Hospital of Eastern Theater Command of Chinese People’s Liberation ArmyNanjingJiangsu 210002P.R.China Department of Medical Oncology Zhejiang Cancer HospitalHangzhouZhejiang 310022P.R.China Cancer Center the First Bethune Hospital of Jilin UniversityChangchunJilin 130021P.R.China Department of Medical Oncology Harbin Medical University Cancer HospitalHarbinHeilongjiang 150081P.R.China Department of Respiratory Medicine Weifang People’s HospitalWeifangShandong

Background:Lipusu is the first commercialized liposomal formulation of pacli-taxel and has demonstrated promising efficacy against locally advanced lung squamous cell carcinoma(LSCC)in a small-scale study.Here,we conducted a multicenter,randomized,phase 3 study to compare the efficacy and safety of cis-platin plus Lipusu(LP)versus cisplatin plus gemcitabine(GP)as first-line treat-ment in locally advanced or metastatic LSCC.Methods:Patients enrolled were aged between 18 to 75 years,had locally advanced(clinical stage IIIB,ineligible for concurrent chemoradiation or surgery)or metastatic(Stage IV)LSCC,had no previous systemic chemother-apy and at least one measurable lesion as per the Response Evaluation Criteria in Solid Tumors(version 1.1)before administration of the trial drug.The primary endpoint was progression-free survival(PFS).The secondary endpoints included objective response rate(ORR),disease control rate(DCR),overall survival(OS),and safety profiles.To explore the possible predictive value of plasma cytokines for LP treatment,plasma samples were collected from the LP group at baseline and first efficacy evaluation time and were then subjected to analysis by 45-Plex ProcartaPlex Panel 1 to detect the presence of 45 cytokines using the Luminex xMAP technology.The correlation between treatment outcomes and dynamic changes in the levels of cytokines were evaluated in preliminary analyses.Results:The median duration of follow-up was 15.4 months.237 patients in the LP group and 253 patients in the GP group were included in the per protocol set(PPS).In the PPS,the median PFS was 5.2 months versus 5.5 months in the LP and GP group(hazard rtio[HR]:1.03,P=0.742)respectively.The median OS was 14.6 months versus 12.5 months in the LP and GP group(HR:0.83,P=0.215).The ORR(41.8%versus 45.9%,P=0.412)and DCR(90.3%versus 88.1%,P=0.443)were also similar between the LP and GP group.A significantly lower proportion of patients in the LP group experienced adverse events(AEs)leading to treatment interruptions(10.9%versus 26.

关键词： chemotherapy cisplatin clinical trial gemcitabine liposomal paclitaxel(Lipusu) locally advanced lung squamous cell carcinoma metastatic multicenter plasma cytokines

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

纺织面料四类污染物的风险监测研究

引用

中国纤检 2024年第6期 44-47页

作者：周爱晖林金美许龚彦林鋆陈拓福建省纤维检验中心、福建省纺织产品检测技术重点实验室福建福州350026

本文陈述了纺织面料污染物监测的重要性,对全氟及全氟化合物、烷基酚和烷基酚聚氧乙烯醚、短链氯化石蜡、邻苯二甲酸酯四类污染物的危害及国内外各法律法规、标准的限定情况展开说明。为进一步分析纺织面料涉及重点管控污染物情况,本文... 详细信息

本文陈述了纺织面料污染物监测的重要性,对全氟及全氟化合物、烷基酚和烷基酚聚氧乙烯醚、短链氯化石蜡、邻苯二甲酸酯四类污染物的危害及国内外各法律法规、标准的限定情况展开说明。为进一步分析纺织面料涉及重点管控污染物情况,本文对不同类型的40批次纺织面料开展全氟及全氟化合物、烷基酚和烷基酚聚氧乙烯醚、短链氯化石蜡、邻苯二甲酸酯四大类污染物的监测,结果表明:40批次纺织面料中,有3批次烷基酚聚氧乙烯醚和1批次全氟辛酸不符合标准要求,对人体健康存在安全隐患。

关键词：纺织面料污染物风险监测

来源：

维普期刊数据库博看期刊

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Polyphenol based hybrid nano-aggregates modified collagen fibers of biological valve leaflets to achieve enhanced mechanical,anticoagulation and anti-calcification properties

引用

Journal of Leather Science and Engineering 2022年第1期4卷 394-408页

作者： Shufen Li Shiying Lang Zhiqian chen Jingruo chen Weihua Zhuang Yangrui Du Yawen Yao gongyan Liu Mao chen Laboratory of Heart Valve Disease West China HospitalSichuan University37 Guoxue AlleyChengdu 610041China The Key Laboratory of Leather Chemistry and Engineering of Ministry of Education College of Biomass Science and EngineeringSichuan UniversityChengdu 610065China University of California Davis 1 Shields AveDavisCA 95616USA Faculty of Science and Engineering Aachen-Maastricht Institute for Biobased Materials(AMIBM)Maastricht UniversityBrightlands Chemelot Campus6167 RD GeleenThe Netherlands Department of Cardiology West China HospitalSichuan University37 Guoxue AlleyChengdu 610041China Regenerative Medicine Research Center West China HospitalSichuan University37 Guoxue AlleyChengdu 610041China

Glutaraldehyde(Glut)-crosslinked porcine pericardium and bovine pericardium are mainly consisted of collagen and widely used for the preparation of heterogenous bioprosthetic heart valves(BHV),which play an important role in the replacement therapy of severe valvular heart disease,while their durability is limited by degeneration due to calcification,thrombus,endothelialization difficulty and prosthetic valve endocarditis.Herein,we develop a novel BHV,namely,TPly-BP,based on natural tannic acid and polylysine to improve the durability of Glut crosslinked bovine pericardium(Glut-BP).Impressively,tannic acid and polylysine could form nanoaggregates via multiple hydrogen bonds and covalent bonds,and the introduction of nanoaggregates not only improved the mechanical properties and collagen stability but also endowed TPly-BP with good biocompatibility and hemocompatibility.Compared to Glut-BP,TPly-BP showed significantly reduced cytotoxicity,improved endothelial cell adhesion,a low hemolysis ratio and obviously reduced platelet adhesion.Importantly,TPly-BP exhibited great antibacterial and in vivo anti-calcification ability,which was expected to improve the in vivo durability of BHVs.These results suggested that TPly-BP would be a potential candidate for BHV.

关键词： Tannic acid Bioprosthetic heart valve Antibacterial and anti-calcification

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

A fully absorbable biomimetic polymeric micelle loaded with cisplatin as drug carrier for cancer therapy

引用

Regenerative Biomaterials 2018年第1期5卷 1-8页

作者： Weihua Zhuang Boxuan Ma gongyan Liu Xiaobing chen Yunbing Wang National Engineering Research Center for Biomaterials Sichuan UniversityChengdu 610064China Department of Biomass Chemistry National Engineering Laboratory of Clean Technology of Leather ManufactureSichuan UniversityChengdu 610064China

cis-dichlorodiammineplatinum(II)(CDDP)-loaded polymeric micelles for cancer therapy have been developed to reduce the serious side effects of cisplatin CDDP.Herein,polymeric micelles incorporated with cisplatin are prepared based on the complexation between CDDP and hydrophilic poly(L-glutamic acid)-b-poly(2-methacryloyloxyethyl phosphorylcholine)(PLG-b-PMPC)diblock copolymers.These CDDP-loaded micelles possess an average size of 91nm with narrow distribution,providing remarkable stability in media containing proteins.The release of CDDP from the micelles is faster at pH 5.0 and pH 6.0 than that at pH 7.4 and in a sustained manner without initial burst release.In addition,there is almost no difference in cellular uptake between these CDDP-loaded micelles and free CDDP.Moreover,in vitro cytotoxicity test shows they possess high efficacy to kill 4T1 cells as compared with free drug.Thus,PLG-b-PMPC copolymer might be a promising carrier for CDDP incorporating in cancer therapy.

关键词： drug delivery cisplatin polymeric micelles cancer therapy

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Current management of chemotherapy-induced neutropenia in adults:key points and new challenges

引用

Cancer Biology & Medicine 2020年第4期17卷 896-909页

作者： Committee of Neoplastic Supportive-Care(CONS),China Anti-Cancer Association Committee of Clinical Chemotherapy,China Anti-Cancer Association Yi Ba Yuankai Shi Wenqi Jiang Jifeng Feng Ying cheng Li Xiao Qingyuan Zhang Wensheng Qiu Binghe Xu Ruihua Xu Bo Shen Zhiguo Luo Xiaodong Xie Jianhua Chang Mengzhao Wang Yufu Li Yuerong Shuang Zuoxing Niu Bo Liu Jun Zhang Li Zhang Herui Yao Conghua Xie Huiqiang Huang Wangjun Liao gongyan chen Xiaotian Zhang Hanxiang An Yanhong Deng Ping Gong Jianping Xiong Qinghua Yao Xin An cheng chen Yanxia Shi Jialei Wang Xiaohua Wang Zhiqiang Wang Puyuan Xing Sheng Yang chenfei Zhou 不详 Department of Gastrointestinal Medical Oncology Tianjin Medical University Cancer Institute and HospitalNational Clinical Research Center for CancerKey Laboratory of Cancer Prevention and TherapyTianjinTianjin's Clinical Research Center for CancerTianjin 300060China Department of Medical Oncology National Cancer CenterCancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100021China Department of Medical Oncology Sun Yat-sen University Cancer CenterGuangzhou 510060China Department of Medical Oncology Jiangsu Cancer HospitalNanjing 210009China Department of Oncology Jilin Province Cancer HospitalChangchun 130012China Department of Oncology Zhongshan Hospital Affiliated to Xiamen UniversityXiamen 361004China Department of Oncology Cancer Hospital Harbin Medical UniversityHarbin 150081China Department of Oncology Affiliated Hospital of Qingdao UniversityQingdao 266003China Department of Medical Oncology Fudan University Shanghai Cancer CenterShanghai 200032China Department of Oncology General Hospital of Shenyang Military RegionShenyang 110016China Department of Pulmonary and Critical Care Medicine Peking Union Medical College HospitalBeijing 100730China Department of Hematology Affiliated Cancer Hospital of Zhengzhou UniversityHenan Cancer HospitalZhengzhou 450008China Lymphoma and Myeloma Department Jiangxi Cancer HospitalNanchang 330029China Department of Medical Oncology Shandong Cancer HospitalShandong Academy of Medical SciencesJinan 250117China Department of Oncology Ruijin HospitalShanghai Jiao Tong University School of MedicineShanghai 200025China MSun Yat-sen Memorial Hospital Sun Yat-sen UniversityGuangzhou 510120China Department of Radiation and Medical Oncology Zhongnan Hospital of Wuhan UniversityWuhan 430070China Department of Oncology Nanfang HospitalSouthern Medical UniversityGuangzhou 510515China Department of Gastrointestinal Oncology Peki ng University Cancer Hospital&InstituteBeijing 100142China Department of

Chemotherapy-induced neutropenia(CIN)is a potentially fatal and common complication in myelosuppressive chemotherapy.The timing and grade of CIN may play prognostic and predictive roles in cancer therapy.CIN is associated with older age,poor functional and nutritional status,the presence of significant comorbidities,the type of cancer,previous chemotherapy cycles,the stage of the disease,specific chemotherapy regimens,and combined therapies.There are many key points and new challenges in the management of CIN in adults including:(1)Genetic risk factors to evaluate the patient’s risk for CIN remain unclear.However,these risk factors urgently need to be identified.(2)Febrile neutropenia(FN)remains one of the most common reasons for oncological emergency.No consensus nomogram for FN risk assessment has been established.(3)Different assessment tools[e.g.,Multinational Association for Supportive Care in Cancer(MASCC),the Clinical Index of Stable Febrile Neutropenia(CISNE)score model,and other tools]have been suggested to help stratify the risk of complications in patients with FN.However,current tools have limitations.The CISNE score model is useful to support decision-making,especially for patients with stable FN.(4)There are still some challenges,including the benefits of granulocyte colony stimulating factor treatment and the optimal antibiotic regimen in emergency management of FN.In view of the current reports,our group discusses the key points,new challenges,and management of CIN.

关键词： Chemotherapy-induced neutropenia(CIN) febrile neutropenia cancer risk stratification granulocyte-colony stimulating factor(G-CSF)

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：